ChemBriefBMS Is Latest Big Pharma Firm to Partner with China’s Hengrui
Bristol Myers Squibb has partnered with Chinese drugmaker Hengrui Pharmaceuticals in a deal potentially worth up to $15.2 billion, featuring a $600 million upfront payment and milestone options.
cen · 2026-05-15 00:00